Dividend Calculator Hub

Bristol-Myers Squibb analysis - BMY dividend pharma

Detailed dividend analysis of BMY - dividend yield, history, payout ratio,

Quick Answer

Is BMY a good dividend stock?

BMY offers a 4.8% dividend yield with 11 years of dividend increases. Analyst rating: Buy.

Key Metrics:

  • Yield: 4.8%
  • Growth History: 11 years
  • Sector: Healthcare
  • Rating: Buy

Company Overview

BMY operates in the Healthcare sector with strong market fundamentals and consistent cash flow generation to support dividends.

Dividend Analysis

The company has demonstrated a strong track record of dividend increases, reflecting management's confidence in future earnings and cash flow growth.

Historical Growth

  • Average annual growth: 5-8%
  • Consistent payout ratios: 30-60%
  • Strong free cash flow coverage

Dividend Safety

Rating: Very Safe

The dividend is supported by:

  • Sustainable payout ratios
  • Strong cash flow generation
  • Stable business fundamentals
  • Management commitment to shareholders

Key Risks

  • Sector-specific challenges
  • Economic sensitivity
  • Market competition
  • Regulatory changes

Analyst Recommendation

Rating: BUY

Financial analysts recommend BMY for dividend-focused investors seeking stable income.

Investment Thesis

BMY is suitable for dividend investors seeking income with growth. The combination of current yield and dividend growth potential makes it attractive for long-term portfolios.

How to Invest

  1. Open a brokerage account (Fidelity, Vanguard, Schwab, etc.)
  2. Search for BMY
  3. Place a buy order
  4. Enable dividend reinvestment (DRIP)
  5. Monitor quarterly earnings

FAQ

1. Is BMY suitable for retirees?

Yes, the dividend yield and growth history make it suitable for retirement income portfolios.

2. How often are dividends paid?

BMY pays dividends quarterly, providing four payments per year.

3. What's the average dividend growth rate?

Approximately 5-8% annually, which helps offset inflation over time.

4. Could the dividend be cut?

While any company faces risks, BMY's fundamentals suggest a cut is unlikely unless major business problems emerge.

5. Should I buy for income or growth?

BMY offers both - immediate income from dividends plus long-term capital appreciation potential.

Disclaimer: This is educational content. Consult a financial advisor before investing.

Last Updated: March 19, 2026

    Bristol-Myers Squibb analysis - BMY dividend pharma | Dividend Engines